Kalohexis 710GO data puts melanocortin obesity drugs back in the metabolic spotlight
GLP-1 drugs dominate obesity care, but Kalohexis is testing a different pathway. 710GO could shift the next weight loss race.
Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?
Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.
Can Anaxiom’s AVOS device open a new minimally invasive route in obesity treatment?
Find out how Anaxiom’s AVOS obesity device could reshape minimally invasive weight-loss treatment after early human results.
How Novo Nordisk may be lowering one of the biggest operational barriers in GLP-1 distribution
Read how Novo Nordisk may be reducing one of the biggest GLP-1 delivery barriers in Europe and what it could mean for Wegovy’s market expansion.
Can Currax and Peek make oral obesity treatment easier to access for self-funded employers?
Currax expands Contrave access through PeekDirect. Read what this could mean for obesity drug pricing, employers, and non-GLP-1 treatment adoption.
Eli Lilly and Company’s Foundayo approval could widen the obesity market faster than rivals expected
Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.
Why the Ro and Eli Lilly KwikPen move matters for obesity drug access, adherence, and pricing
Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.
What the Hims & Hers Health, Inc. and Novo Nordisk collaboration reveals about the future of obesity drug commercialization
Explore how Hims & Hers and Novo Nordisk are expanding GLP-1 access and what it means for obesity care, pricing, and regulation.
Why TIXiMED’s TIX100 data highlights a growing therapeutic gap after GLP-1 weight-loss treatment
TIXiMED reports preclinical data showing oral TIX100 may prevent weight regain after GLP-1 therapy. Discover what this could mean for obesity treatment.
What Veru Inc.’s Phase 2b PLATEAU trial signals about the evolution of combination obesity drugs
Veru Inc. launches Phase 2b PLATEAU trial combining enobosarm with semaglutide for obesity. Discover what it means for next-generation weight-loss drugs.